Use of Tissue Specimens from Stereotactic Biopsies for Patient-Derived GBM Organoid-Based Drug Testing.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101600052 Publication Model: Electronic Cited Medium: Internet ISSN: 2073-4409 (Electronic) Linking ISSN: 20734409 NLM ISO Abbreviation: Cells Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI

Organoids*/pathology ; Organoids*/drug effects ; Glioblastoma*/pathology ; Glioblastoma*/drug therapy ; Brain Neoplasms*/pathology ; Brain Neoplasms*/drug therapy ; Stereotaxic Techniques*; Humans ; Biopsy/methods ; Drug Screening Assays, Antitumor/methods

Competing Interests: The authors declare no conflicts of interest.
IDH -wildtype glioblastoma (GBM) represents the most common malignant form of brain tumor and is still incurable despite comprehensive therapeutic efforts. Due to tumor location and patient condition, open surgical resection of recurrent GBM is not always feasible. In these cases, frame-based stereotactic biopsies represent a less invasive technique to obtain tissue samples for diagnostics. However, whether this material would also be sufficient to prepare tumor organoids (TOs) and perform drug screenings has not been addressed so far. In this study, we present our highly optimized workflow for generating standardized patient-derived GBM TOs from single-cell suspensions using limited biopsy-derived material. We highlight crucial steps within the procedure, such as reliable cell counting, viable cell recovery, enzymatic digestion, and the requirement of an extracellular matrix as a scaffold. Furthermore, we showcase the potential of personalized drug testing as a promising application of GBM TOs. In conclusion, we successfully developed a robust workflow that effectively utilizes the limited material derived from stereotactic biopsies to reproducibly form standardized TOs. Moreover, we demonstrate that biopsy-derived TOs represent a valuable tool for testing drug vulnerabilities in a personalized setting, which might be especially useful in the case of non-resectable GBM.

J Immunol Methods. 2013 Feb 28;388(1-2):25-32. (PMID: 23201386)
J Neurooncol. 2020 Apr;147(2):297-307. (PMID: 32157552)
Nat Protoc. 2020 Dec;15(12):4000-4033. (PMID: 33169003)
Biotechnol Rep (Amst). 2015 Apr 18;7:9-16. (PMID: 28626709)
Cells. 2021 Feb 24;10(3):. (PMID: 33668200)
J Neurosci Rural Pract. 2018 Jan-Mar;9(1):86-91. (PMID: 29456350)
Cells. 2023 Apr 20;12(8):. (PMID: 37190109)
J Neurooncol. 1999 May;42(3):205-13. (PMID: 10433104)
Front Oncol. 2018 Nov 08;8:503. (PMID: 30467536)
Cell Mol Life Sci. 2025 Jan 21;82(1):52. (PMID: 39833546)
Cancer Treat Rev. 2020 Jul;87:102029. (PMID: 32408220)
Neurooncol Adv. 2021 Jul 26;3(1):vdab100. (PMID: 34466804)
Cancer Manag Res. 2019 Feb 25;11:1843-1855. (PMID: 30881112)
Surg Neurol. 1980 Oct;14(4):275-83. (PMID: 7001660)
Chemistry. 2022 Jun 15;28(34):e202201362. (PMID: 35616165)
Acta Neuropathol. 2020 Dec;140(6):919-949. (PMID: 33009951)
Am J Physiol Cell Physiol. 2023 Dec 1;325(6):C1451-C1469. (PMID: 37899749)
Front Oncol. 2021 Jan 29;10:614295. (PMID: 33585240)
Cancer Res. 2016 Apr 15;76(8):2465-77. (PMID: 26896279)
Acta Neuropathol. 2007 Aug;114(2):97-109. (PMID: 17618441)
Neurosurgery. 1984 Oct;15(4):502-8. (PMID: 6387527)
Nat Commun. 2025 Apr 28;16(1):3957. (PMID: 40295505)
Cell. 2020 Jan 9;180(1):188-204.e22. (PMID: 31883794)
Clin Cancer Res. 2023 Nov 14;29(22):4685-4697. (PMID: 37682326)
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95. (PMID: 36196752)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
J Biotechnol. 2019 Nov 10;305:23-26. (PMID: 31442502)
Cancers (Basel). 2023 Apr 01;15(7):. (PMID: 37046777)

Dietmar Hopp Stiftung; 404521405 Deutsche Forschungsgemeinschaft

Keywords: glioblastoma; patient-derived tumor organoids; precision medicine; stereotactic biopsy

Date Created: 20250527 Date Completed: 20250527 Latest Revision: 20250530

20250530

PMC12109714

10.3390/cells14100701

40422204